

PERSONAL INFORMATION

Name: GIARRATANO Tommaso

Date and place of birth: December 06, 1983; San Cataldo (CL) - Italy

Nationality: Italian

Work address: Oncologia Medica 2 – I.O.V. I.R.C.C.S; Via Gattamelata 64, 35128 Padova, Italy

Telephone and email: 049/8215931 – tommaso.giar ratano@iov.veneto.it

EDUCATION

2011-2016 Training in Medical Oncology - University of Padua (Italy)

February 2011 Italian medical license

2004-2010 Medical degree - University of Palermo (Italy)

WORK EXPERIENCE

01/2018 - present Medical Oncologist - Istituto Oncologico Veneto IRCCS Medical Oncology 2 Unit, Padova

07/2016 -12/2017 Research fellow - Department of Surgery, Oncology and Gastroenterology, University of Padua, Italy

07/2016 -12/2017 Medical Oncologist - Istituto Oncologico Veneto IRCCS Medical Oncology 2 Unit, Padova

RESEARCH EXPERIENCE

06/2013 – 06/2016 Medical Oncologist in Training - Department of Surgery, Oncology and Gastroenterology, University of Padua, Italy Focus on clinical and research activities in breast cancer

06/2011 – 06/2013 Medical Oncologist in Training - Department of Surgery, Oncology and Gastroenterology, University of Padua, Italy

PUBLICATIONS

1. **Tommaso Giar ratano**, Federica Miglietta, Carlo Alberto Giorgi, Vassilena Tsvetkova, Silvia Michieletto, Laura Evangelista, Ilaria Polico, Maria Vittoria Dieci and Valentina Guarneri. Exceptional and durable responses to TDM-1 after trastuzumab failure for breast cancer skin metastases. *Frontiers in Oncology Women's Cancer*, December 2018 doi: 10.3389/fonc.2018.00581.
2. Griguolo G, Dieci MV, **Giar ratano T**, Giorgi CA, Orvieto E, Ghiotto C, Berti F, Della Puppa A, Falci C, Mioranza E, Tasca G, Milite N, Miglietta F, Scienza R, Conte P, Guarneri V. Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome. *J Neurooncol*. 2017 Jan;131(2):369-376.
3. Dieci MV, Ghiotto C, Barbieri C, Griguolo G, Saccardi C, Gangemi M, Pluchinotta A, Di

- Liso E, Giorgi CA, **Giarratano T**, Tasca G, Vernaci G, Faggioni G, Conte P, Guarneri V. Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center. *J Womens Health (Larchmt)*. 2018 Jul 2.
4. Dieci MV, Tsvetkova V, Orvieto E, Piacentini F, Ficarra G, Griguolo G, Miglietta F, **Giarratano T**, Omarini C, Bonaguro S, Cappellesso R, Aliberti C, Vernaci G, Giorgi CA, Faggioni G, Tasca G, Conte P, Guarneri V. Immune characterization of breast cancer metastases: prognostic implications. *Breast Cancer Res*. 2018 Jun 22;20(1):62.
 5. Dieci MV, Guarneri V, **Giarratano T**, Mion M, Tortora G, De Rossi C, Gori S, Oliani C, Pasini F, Bonciarelli G, Griguolo G, Orvieto E, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte PF. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer. *Oncologist*. 2018 Mar;23(3):297-305
 6. Dieci MV, Guarneri V, Zustovich F, Mion M, Morandi P, Bria E, Merlini L, Bullian P, Oliani C, Gori S, **Giarratano T**, Orvieto E, Griguolo G, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P; Veneto Oncology Network. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study. *Oncologist*. 2019 May 31. pii: theoncologist.2019-0103. doi: 10.1634/theoncologist.2019-0103.
 7. Dieci MV, Tsvetkova V, Griguolo G, Miglietta F, Mantiero M, Tasca G, Cumerlato E, Giorgi CA, **Giarratano T**, Faggioni G, Falci C, Vernaci G, Menichetti A, Mioranza E, Di Liso E, Frezzini S, Saibene T, Orvieto E, Guarneri V. Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease. *Front Oncol*. 2019 Jun 6;9:452. doi: 10.3389/fonc.2019.00452. eCollection 2019.
 8. Conte P, Frassoldati A, Bisagni G, Brandes AA, Donadio M, Garrone O, Piacentini F, Cavanna L, Giotto F, Aieta M, Gebbia V, Molino A, Musolino A, Ferro A, Maltoni R, Danese S, Zamagni C, Rimanti A, Cagossi K, Russo A, Pronzato P, Giovanardi F, Moretti G, Lombardo L, Schirone A, Beano A, Amaducci L, Bajardi EA, Vicini R, Balduzzi S, D'Amico R, Guarneri V. Collaborators: Falci C, **Giarratano T**, McMahon L, De Salvo GL, Dieci MV, Maiorana A, Ficarra G, Caggia F, Grisolia D, Bartolini S, Lorusso V, Ardito R, Tartarone A, Vanella P, Taverniti C, Porpiglia M, Spanu PG, Biglia N, Andreis D, Piancastelli A, Fedeli A, Parra HS, Gambaro AR, Romito S, Malossi A, Gori S, Miglietta L, Del Mastro L, Amoroso D, Mansutti M, Generali D, Prati G, Bertolini A, Berardi R, Zanni A, Cottafavi L, Bologna A, Naso G, Pancotti A, Farci D, Zoboli A, Silva R, Laudadio L, Bordonaro R, Marengo D, Dongiovanni V, Baldini E, Saggia C, Gorzegno G, Cariello A, Biganzoli L, Rampello E. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. *Ann Oncol*. 2018 Dec 1;29(12):2328-2333. doi: 10.1093/annonc/mdy414

James Randi